HPS3 / TIMI 55 - REVEAL : Randomised EValuation of the Effects of Anacetrapib through Lipid-modification
REVEAL is a randomised trial investigating the effects of adding anacetrapib (a potent CETP inhibitor) to effective LDL-lowering treatment with atorvastatin. Between 2011 and 2013 REVEAL recruited over 30,000 men and women who already had some form of circulatory disease. Participants were recruited from over 430 hospitals and clinics in the UK, North America, China, Germany, Italy and Scandinavia. All study participants were given atorvastatin (a commonly used "statin" drug) to ensure good control of LDL ("bad") cholesterol. Participants also received either anacetrapib 100mg or matching placebo (dummy) tablets daily (allocated randomly).
The primary aim of the study was to see whether fewer participants given anacetrapib had heart attacks, revascularization procedures or died from coronary heart disease than those given the placebo tablets. Secondary aims included assessment of the safety of anacetrapib, as well as the effects on a number of other outcomes.
The trial was coordinated at CTSU, with academic collaborators leading regional coordinating centres in Europe, North America and China. The University of Oxford is the trial Sponsor. Financial support has been provided by Merck Sharp & Dohme.
Results were published in 2017 and showed that anacetrapib lowers the risk of heart attack and related cardiovascular complications among high risk patients who are receiving intensive statin treatment. The treatment was well tolerated and there were no major safety concerns.
Long-term follow-up information
All participants stopped study treatment prior to February 2017 and direct participant follow-up was completed in April 2019. However, in the UK we continue to collect information on health outcomes via central data registries and NHS sources.